Business
Parsortix system showcased at NCRI Festival
Parsortix system showcased at NCRI Festival.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 0200S\n Angle PLC\n 11 November 2021\n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n 11 November 2021\n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n ANGLE'S PARSORTIX SYSTEM SHOWCASED IN POSTER PRESENTATION AT NATIONAL CANCER RESEARCH INSTITUTE (NCRI) FESTIVAL \n \n \n \n \n \n Study in metastatic prostate cancer presented at NCRI Festival demonstrates longitudinal analysis of CTCs harvested using the Parsortix system is predictive of treatment response\n \n \n \n \n \n KLK2 gene expression on CTCs found to be a more effective biomarker for assessing likelihood of cancer progression than current standard of care\n \n \n \n \n \n \n \n \n ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, \n is pleased to announce that a poster presentation showcasing the Parsortix® system was presented yesterday at the National Cancer Research Institute (NCRI) Festival, being held 8-12 November 2021. The poster showcases findings from a Barts Cancer Institute study in metastatic prostate cancer which undertook circulating tumour cell (CTC) analysis to evaluate docetaxel drug treatment response and resistance markers.\n \n \n \n \n \n Longitudinal CTC sampling was performed using the Parsortix system in 56 patients. The samples were taken before patients started docetaxel treatment, during treatment, and after completing all doses over a period of 6-8 months. A total of 205 CTC samples were analysed for changes in CTC number, phenotype, and mRNA gene expression.\n \n \n \n \n \n Multiplex qPCR analysis, using a custom designed 32 gene panel of CTC mRNA revealed that patients with disease progression who have worse predicted survival rates had high expression of the KLK2 gene at each blood collection time point and that this was significantly more predictive than the current standard of care for assessing the likelihood of progression, which is based on blood PSA levels. These findings are significant as they highlight KLK2 as a possible alternative and a better biomarker for prostate cancer prognosis.\n \n \n \n \n \n This study concludes that longitudinal analysis of CTCs isolated using the Parsortix system can predict whether a patient is resistant or developing resistance to treatment with docetaxel...